Boston, MA 09/08/2014 (wallstreetpr) – Recently Genocea Biosciences Inc (NASDAQ:GNCA) presented phase 1 immunology data from an investigational vaccine named GEN-004, which is designed to prevent disease that is caused by serotypes of pneumococcus.
Insights of this presentation:
Genocea Biosciences Inc (NASDAQ:GNCA) made a presentation at ICAAC in which it revealed the phase 1 data from its initial study which was executed to prevent serotypes of pneumococcus disease. The data presented by the company showed that the study met immunogenicity, tolerability and safety objectives. The results included the inclination in the blood of T helper 17 cells. These are special and rare cells that provide immunity at mucosal and epithelial surfaces.
According to experts, immunization with GEN-004 may reduce pneumococcus colonization in the nasopharynx with the help of TH17 T cell-mediated immune response. It is a precursor to infection that is caused by almost all the serotypes of pneumococcus. Total 90 volunteers were involved in the phase 1 study. All the volunteers were adults and healthy to prevent any adverse effect afterwards. The main objective of this study was to analyze the tolerability and safety of GEN-004. As per the reports, it was comprised of three main protein antigens i.e. SP2108, SP0148 and SP1912. The only condition set by researchers was to analyze the results without availability of aluminum hydroxide as an adjuvant.
Researchers randomized all the subjects to attain 10, 30 or 100 µg of each dose in the presence or absence of placebo or 350µg aluminum hydroxide. All the participants were made receive three doses each for four weeks. The results of GEN-004 were analyzed with the help of an intramuscular injection.
Results of the study:
At the end of the study, researchers found that GEN-004 was tolerated and safe at all doses after the administration of around 85 days. Commonly occurred side effects were pain, muscle aches, tenderness and fatigue.
